What Is BPC-157? A Comprehensive Research Guide

What exactly is BPC-157?

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide — fifteen amino acids long — derived from a protective protein found in human gastric juice. Its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) doesn't match any known naturally occurring peptide in full, which makes it something of an oddity in peptide science. It's technically a partial sequence of the larger BPC protein isolated from gastric secretions, but the 157 fragment itself is lab-synthesised.

What's drawn so much research attention is the breadth of tissue types BPC-157 appears to affect. Unlike most peptides that act on a narrow receptor set, BPC-157 has been investigated across gastrointestinal, musculoskeletal, vascular, and neurological models — and the early data from preclinical work is, frankly, striking. The peptide was first characterised by Professor Predrag Sikiric's group at the University of Zagreb, and the majority of published work still originates from Croatian research teams, though international interest has expanded rapidly over the past decade.

The molecular weight of BPC-157 is 1419.53 Da in its free acid form and 1584.76 Da as the acetate salt. Both forms are commercially available, and researchers should verify which form they're working with — the difference matters when calculating molar concentrations. The free acid form is generally preferred for research applications due to better stability and the absence of the TFA counterion.

How does BPC-157 work at the molecular level?

The mechanism of action isn't fully mapped, but several pathways have emerged from the literature. BPC-157 appears to upregulate growth factor expression — particularly VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor) — which are central to angiogenesis and tissue repair. Research by Sikiric et al. (2018) demonstrated that BPC-157 modulates the nitric oxide (NO) system, interacting with both NO synthase and the NO-cGMP signalling pathway (DOI: 10.2174/1389203719666180517152953).

There's also evidence of interaction with the FAK-paxillin pathway, which governs cell migration and adhesion. In practical terms, this suggests the peptide may accelerate the rate at which cells organise themselves during wound repair. Some researchers have proposed a connection to the dopaminergic system as well — BPC-157 appears to influence D2 receptor sensitivity, though the clinical significance of this in humans remains entirely theoretical.

One particularly interesting observation is BPC-157's apparent effect on the GI tract's own repair mechanisms. Given its origin in gastric juice, it's perhaps not surprising that it seems most potent in gastrointestinal models. The peptide has been shown to interact with the endothelial and enterocyte junction systems, potentially tightening epithelial barriers — a finding with implications for leaky gut models and intestinal permeability research.

What about the JAK-2/STAT-3 pathway?

More recent investigations have identified JAK-2/STAT-3 signalling as another potential mediator. This pathway is deeply involved in cytokine signalling and cellular growth responses. If confirmed, it would help explain BPC-157's apparent ability to influence such a diverse range of tissue types — JAK-STAT signalling is nearly universal across mammalian cell populations. However, this work is early-stage and the findings are based on a limited number of rodent studies.

What have animal studies shown?

The preclinical literature on BPC-157 is extensive — over 100 published studies, nearly all in rodent models. Key findings include:

- Tendon and ligament repair: Accelerated healing in Achilles tendon transection models, with increased collagen organisation and mechanical strength (Chang et al., 2011; DOI: 10.1002/jor.21372). The tendon studies are among the most replicated findings in the BPC-157 literature.

- Gastric protection: Significant cytoprotection against NSAID-induced gastric lesions, alcohol damage, and stress ulcers. BPC-157 appears to maintain mucosal integrity even under severe chemical insult. This has been demonstrated across multiple NSAID types, including diclofenac and indomethacin models.

- Vascular repair: Promotion of angiogenesis in ischaemic models. Blood vessel formation was consistently enhanced, and BPC-157 appeared to counteract the effects of vessel-blocking agents. In one notable study, BPC-157 rescued blood flow in a surgically created ischaemic limb model within days of treatment.

- Neurological effects: Reduced damage in models of traumatic brain injury. Some studies report improvements in spatial learning tasks post-injury, though these findings require replication.

- Muscle healing: Accelerated recovery in crushed muscle models, with improved force generation at earlier time points compared to controls.

- Bone repair: A smaller body of work suggests BPC-157 may influence osteoblast activity and bone healing, though the evidence is preliminary.

It's worth stressing that these are all animal studies. The leap from rat models to human physiology is substantial, and no controlled human clinical trials have been completed to date. Researchers should treat the existing data as hypothesis-generating rather than confirmatory. The Zagreb group has repeatedly called for Phase I human trials, but funding and regulatory hurdles have slowed progress.

What is the typical research protocol?

For in vitro work, BPC-157 is typically dissolved in bacteriostatic water at concentrations ranging from 10 to 100 µg/mL, depending on the cell line and assay. The peptide is stable across a wide pH range (pH 2–10), which is unusual for peptides and likely relates to its gastric origin. Cell culture studies commonly use 24-well or 96-well plates with treatment durations of 24–72 hours.

For in vivo rodent studies, doses in the published literature range from 10 µg/kg to 10 mg/kg administered intraperitoneally, though most efficacy has been reported at the lower end of this range — typically 10–50 µg/kg. Both intraperitoneal and oral administration routes have shown activity, which is remarkable for a peptide and speaks to BPC-157's unusual stability in the GI tract. Some protocols use topical application for wound-healing studies, incorporating BPC-157 into gel or cream vehicles.

Researchers should consult Read more for full specification sheets and our Read more for accurate dilution calculations.

Stability considerations

BPC-157 is more stable than most peptides of its size — it resists degradation in gastric acid, which is a direct consequence of its biological origin. Lyophilised powder should be stored at -20°C for long-term stability, though short-term storage at 2–8°C is acceptable. Once reconstituted, use within 7–14 days and keep refrigerated. The peptide's exceptional pH stability means it maintains activity even in acidic environments where most peptides would denature rapidly — a property that distinguishes it from virtually all other research peptides on the market.

How is BPC-157 purity verified?

Any reputable supplier should provide HPLC (high-performance liquid chromatography) analysis confirming purity above 98%. Mass spectrometry confirmation of the molecular weight (1419.53 Da for the free acid form) is equally important. Researchers should always request a Read more Certificate of Analysis before beginning experimental work.

Impurities in synthetic peptides can include truncated sequences, deletion peptides, and residual TFA (trifluoroacetic acid) from solid-phase synthesis. These impurities can confound experimental results — particularly in cell-based assays where even trace contaminants alter viability readings. For BPC-157 specifically, the most common synthesis impurities are deletion peptides lacking one of the three consecutive proline residues (positions 4–6), since repeated proline couplings are notoriously challenging in solid-phase synthesis.

What are the current gaps in BPC-157 research?

Despite the volume of preclinical data, several critical questions remain:

1. No human trial data — the entire evidence base is preclinical. Until randomised controlled trials are conducted, efficacy and safety in humans are unknown.

2. Unclear receptor binding — while downstream effects are documented, the primary receptor target (if one exists) hasn't been definitively identified. This is unusual for a peptide with such pronounced biological effects.

3. Dose-response relationships — most studies use a narrow dose range, and systematic dose-response curves are rare. We don't yet know the minimum effective dose or the ceiling beyond which additional peptide provides no benefit.

4. Long-term effects — the longest animal studies span weeks. Chronic exposure data is essentially absent, and potential cumulative effects are unknown.

5. Pharmacokinetics — absorption, distribution, metabolism, and excretion (ADME) data is sparse. How BPC-157 is processed by the body and how quickly it's cleared remain open questions.

These gaps represent genuine opportunities for researchers. The peptide's unusual stability, broad tissue activity, and favourable toxicity profile in animals make it an attractive candidate for further investigation.

Where does BPC-157 research stand in 2026?

Interest continues to grow. PubMed listings for BPC-157 have increased year on year, and several research groups are exploring its potential in combination with other peptides — notably TB-500, which acts via complementary but distinct mechanisms. The so-called "Wolverine stack" pairing is a popular area of investigation, covered in detail in our comparison article.

New areas of enquiry include BPC-157's effects on gut-brain axis signalling, its potential in inflammatory bowel disease models, and whether its vascular effects could be harnessed in diabetic wound-healing contexts where angiogenesis is impaired. There's also growing interest in BPC-157's interaction with the microbiome, though this line of research is very early indeed.

For UK researchers sourcing BPC-157, purity documentation and batch consistency are non-negotiable requirements. Premio Peptides provides full third-party analytical data with every order — see our Read more page for details.

References

1. Sikiric, P. et al. (2018). "Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications." *Current Neuropharmacology*, 16(5), 566–583. DOI: 10.2174/1570159X16666180117142938

2. Chang, C.H. et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." *Journal of Orthopaedic Research*, 29(6), 923–930. DOI: 10.1002/jor.21372

3. Seiwerth, S. et al. (2014). "BPC 157 and standard angiogenic growth factors." *Current Pharmaceutical Design*, 20(7), 1014–1029. DOI: 10.2174/138161282007140327115557

---

Research Use Only Disclaimer

All peptides sold by Premio Peptides are strictly for laboratory and research purposes. They are not intended for human consumption, therapeutic use, or as food supplements. Researchers are responsible for ensuring compliance with all applicable regulations in their jurisdiction. Premio Peptides does not condone or encourage the use of these products outside a controlled research environment.

*Published by the Premio Peptides research team. Peer-reviewed sources cited throughout.*